The company's discovery services support a wide range of global innovator companies from start-ups to large pharma companies, across a diverse set of therapeutic areas including oncology, CNS, antivirals, and inflammation among others
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
Capital infusion to accelerate Earendil’s R&D platform
The Institute of Human Biology (IHB) enables scientists to pioneer human model systems, accelerating the development of new medicines to improve the lives of patients
The patent protects antiviral compounds developed by the company that inhibit Vacuolar ATPase (V-ATPase) activity in cells, a mechanism involved in viral infection pathways
The initiative will be led by David Baker, 2024 Nobel Prize winner in Chemistry, IPD director, professor of biochemistry, and HHMI Investigator at the University of Washington
The move opens Japan’s advanced life science market to Epigenica’s high-throughput epigenetic profiling kits
The kit features ViaPlex 405 Barcoding Dye for the 405 nm laser/Pacific Blue filter and ViaPlex 488 Barcoding Dye for the 488 nm laser/FITC filter
The facility supports drug discovery, biomolecular research, and the development of next-generation diagnostics
The facility features 2,176 high-performance GPUs across the US and Europe
Subscribe To Our Newsletter & Stay Updated
